Proscia

AI-powered pathology for precision medicine

Philadelphia, Pennsylvania, United States

Precision Medicine/Diagnostics AI / ML CancerSeries D+

Proscia is a digital pathology company offering the Concentriq platform, which provides AI-powered virtual staining and integrates with molecular tests and pathology reports to enhance diagnostic capabilities.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Proscia on @MedStartr Today Proscia is a digital pathology company offering the Concentriq platform, which provides AI-powered virtual staining and integrates with molecular tests and pathology reports to enhance diagnostic capabilities. #Immunology #CardiometabolicDiseases #MentalBehavioralHealth #CancerOncology #PrecisionMedicineDiagnostics #AIML #Cancer #MedMo #MedStartrVentures

https://www.medstartr.ai/s/CM7rith5Lig

Get Involved in Proscia

1 engagement

How We Help

Problem Statement

Proscia addresses the challenges in traditional pathology by providing a digital pathology platform that improves diagnostic efficiency and accuracy through AI-powered virtual staining and integration with molecular and pathology data.

Core Technology

The Concentriq platform for digital pathology, including an AI-powered virtual staining capability that generates H&E, IHC, and special stains on-demand. It integrates with molecular tests and pathology reports.

Key Differentiators

OEM agreement with Siemens Healthineers for integration into Siemens Enterprise Imaging for the global digital pathology market; Distribution partnership with Agilent Technologies for digital pathology solutions; AI-powered virtual staining capability powered by Pictor Labs technology

Clinical Focus

Pathology

Company Info

Business Model: B2B
Founded: 2014
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: proscia.com/

Disease Areas

Immunology Cardiometabolic Diseases Mental Health Cancer & Oncology

Technologies

Digital PathologyVirtual StainingAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

FDA 510(k) cleared (K230839, Feb 2024); multi-site clinical study showing -0.1% major discordance vs. glass slides; 98% accuracy in skin biopsy classification; largest AI validation study in pathology

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Proscia?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.